Profound Med Stock Price, News & Analysis
Company Description
Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) is a commercial-stage medical device company in the surgical and medical instrument manufacturing industry. The company develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, with a focus on transforming how prostate disease and certain other conditions are treated.
According to company disclosures, Profound’s core platform is TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, is described as an incision- and radiation-free, single-session treatment that uses directional ultrasound from inside the urethra to gently heat prostate tissue to 55–57°C while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure.
TULSA-PRO and the TULSA Procedure
Profound states that the TULSA Procedure has the potential to become a mainstream treatment modality across the entire prostate disease spectrum. This includes low-, intermediate-, and high-risk prostate cancer; men with both prostate cancer and benign prostatic hyperplasia (BPH); men with BPH only; and patients requiring salvage therapy for radio-recurrent localized prostate cancer. The procedure is designed to preserve urinary continence and sexual function while ablating targeted prostate tissue.
The company highlights several procedural characteristics: virtually all prostate shapes and sizes can be treated; there is no procedural blood loss; no hospital stay is required; and most patients are reported to return quickly to their normal routine. TULSA-PRO is described as CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (FDA).
Profound’s news releases also describe the TULSA-PRO system as the only AI-powered, MRI-guided robotic system for prostate therapy, enabling physicians to see, monitor and adjust treatment throughout the procedure using real-time MRI thermography and autonomous temperature control.
AI and Workflow Modules
In addition to TULSA-PRO’s core capabilities, Profound has announced the TULSA-AI® Volume Reduction module, designed for optimizing treatment of patients with BPH. The company indicates that this module uses AI to streamline workflow and reduce procedure times for enlarged prostate treatment, while using the same device hardware and clinical support staff. Profound states that this supports efficient scheduling of multiple prostate cases in a day and is intended to make use of TULSA-PRO for BPH as efficient as other modern procedures, while maintaining precision and customization to any prostate shape or size.
Sonalleve Therapeutic Platform
Beyond prostate-focused technologies, Profound is also commercializing Sonalleve®, described as a therapeutic platform for non-invasive ablation. According to company descriptions, Sonalleve is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. It has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma.
Profound reports that it is in the early stages of exploring additional potential treatment markets for Sonalleve in areas where the technology has shown clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Clinical and Market Adoption
Profound’s disclosures emphasize growing clinical use of the TULSA Procedure. The company has highlighted treatment of prostate cancer and BPH patients at institutions such as The Johns Hopkins Hospital, Mount Sinai Hospital, and centers including the Busch Center and Texas Prostate in collaboration with Dallas Medical Center. These sites are described as using TULSA-PRO in interventional MRI suites as part of a broader movement toward MRI-guided therapies.
The company reports that its installed base of TULSA-PRO systems reached 78 systems as of December 31, 2025, with a qualified sales pipeline of additional systems in stages such as “Verify,” “Negotiate” and “Contracting.” Profound characterizes its revenue mix as including recurring non-capital revenue from TULSA-PRO consumables, equipment leases and extended warranty services, alongside one-time capital equipment sales.
Regulatory Status and Geography
Profound Medical Corp. is incorporated in Ontario, Canada and reports under U.S. securities regulations with a Commission File Number of 001-39032. The company has disclosed distribution and supply agreements for TULSA-PRO and Sonalleve in multiple regions, including exclusive arrangements in Canada, Saudi Arabia, Australia and New Zealand through local partners. These agreements are intended to support adoption of its technologies in various healthcare systems.
Business Model
From its public communications, Profound’s business model centers on the development, commercialization and ongoing support of medical device platforms for image-guided ablation. Revenue sources identified by the company include:
- Sale and lease of TULSA-PRO capital equipment.
- Recurring non-capital revenue from TULSA-PRO consumables and extended warranty services.
- Commercialization of Sonalleve systems for approved indications in multiple jurisdictions.
The company also raises capital through registered direct offerings and private placements of common shares, with stated uses of proceeds including expansion of sales and marketing, working capital, research and development, strategic transactions and general corporate purposes.
Position Within Surgical and Medical Instrument Manufacturing
Within the broader surgical and medical instrument manufacturing sector, Profound focuses on MRI-guided, energy-based ablation technologies that aim to reduce or eliminate the need for incisions and hospital stays in certain procedures. Its emphasis on AI-enhanced planning, robotic control and real-time MRI thermography is central to its product positioning as described in its news releases and regulatory filings.
Frequently Asked Questions
Stock Performance
Latest News
SEC Filings
Financial Highlights
Upcoming Events
Q4 and FY2025 results release
Management conference call
U.S. registration filing deadline
Resale hold expiry
Hold period expiration
Short Interest History
Short interest in Profound Med (PROF) currently stands at 1.2 million shares, up 7.9% from the previous reporting period, representing 3.9% of the float. Over the past 12 months, short interest has increased by 156.3%. This relatively low short interest suggests limited bearish sentiment. The 5.5 days to cover indicates moderate liquidity for short covering.
Days to Cover History
Days to cover for Profound Med (PROF) currently stands at 5.5 days, down 60.4% from the previous period. This moderate days-to-cover ratio suggests reasonable liquidity for short covering, requiring about a week of average trading volume. The days to cover has decreased 22.6% over the past year, suggesting improved liquidity for short covering. The ratio has shown significant volatility over the period, ranging from 2.8 to 20.9 days.
